Paroxetine: an update of its use in psychiatric disorders in adults.

@article{Wagstaff2002ParoxetineAU,
  title={Paroxetine: an update of its use in psychiatric disorders in adults.},
  author={A. Wagstaff and S. Cheer and A. Matheson and D. Ormrod and K. Goa},
  journal={Drugs},
  year={2002},
  volume={62 4},
  pages={
          655-703
        }
}
  • A. Wagstaff, S. Cheer, +2 authors K. Goa
  • Published 2002
  • Medicine
  • Drugs
  • Paroxetine is a selective serotonin reuptake inhibitor (SSRI), with antidepressant and anxiolytic activity. In 6- to 24-week well designed trials, oral paroxetine 10 to 50 mg/day was significantly more effective than placebo, at least as effective as tricyclic antidepressants (TCAs) and as effective as other SSRIs and other antidepressants in the treatment of major depressive disorder. Relapse or recurrence over 1 year after the initial response was significantly lower with paroxetine 10 to 50… CONTINUE READING
    109 Citations
    Paroxetine: current status in psychiatry
    • 40
    Paroxetine: safety and tolerability issues
    • 31
    Paroxetine in the treatment of generalised anxiety disorder
    • 11
    • Highly Influenced
    Paroxetine Controlled Release
    • 26
    Paroxetine for the treatment of depression: a critical update
    • 17

    References

    SHOWING 1-10 OF 168 REFERENCES
    Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.
    • 14
    Paroxetine. An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders.
    • 133
    • Highly Influential
    Fluoxetine : A review of its use in anxiety disorders and mixed anxiety and depression
    • 30
    A Canadian multicenter, double-blind study of paroxetine and fluoxetine in major depressive disorder.
    • 63
    • Highly Influential
    Paroxetine in the treatment of depression
    • 43
    Paroxetine and amitriptyline augmentation of lithium in the treatment of major depression: a double-blind study.
    • 30
    A double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients.
    • 88
    • Highly Influential
    Controlled comparison of paroxetine and fluvoxamine in major depression
    • 22
    • Highly Influential
    Paroxetine versus amitriptyline for treatment of depression associated with rheumatoid arthritis: a randomized, double blind, parallel group study.
    • 51
    • Highly Influential
    Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison.
    • M. Poirier, P. Boyer
    • Medicine, Psychology
    • The British journal of psychiatry : the journal of mental science
    • 1999
    • 202